(ACT) Enact Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29249E1091
ACT: Mortgage Insurance, Reinsurance, Underwriting Services
Enact Holdings, Inc. (NASDAQ:ACT), operating under the banner of private mortgage insurance, is a pivotal player in the U.S. residential mortgage sector. Their core business revolves around underwriting and assuming mortgage guaranty insurance, essentially mitigating the risk for lenders offering high loan-to-value mortgages. This role is crucial in expanding homeownership, though it comes with inherent risks tied to economic fluctuations and housing market dynamics.
The companys service portfolio extends beyond insurance, encompassing contract underwriting and mortgage-related reinsurance. These offerings not only diversify their revenue streams but also illustrate a strategic approach to risk management. By reinsuring portions of their insurance portfolio, Enact effectively balances its exposure, a prudent move in an industry sensitive to economic shifts.
Originally known as Genworth Mortgage Holdings, Enact rebranded in 2021, signaling a new chapter while retaining its foundational expertise. Founded in 1981 and headquartered in Raleigh, North Carolina, Enact functions as a subsidiary of Genworth Holdings, Inc., leveraging this relationship for operational and strategic support.
From a financial standpoint, Enacts market capitalization exceeds $5 billion, underscoring its significant presence in the industry. The P/E ratio of 7.67 reflects moderate growth expectations, typical of a sector often valued for stability over rapid expansion. The P/S ratio of 4.30 indicates a reasonable valuation relative to revenue, suggesting a balance between market value and revenue generation.
For investors and fund managers, Enact presents an opportunity in a niche market with clear risk and return dynamics. The companys operational resilience and strategic risk management practices position it as a stable investment in the mortgage insurance landscape, where economic trends and regulatory changes play pivotal roles.
Additional Sources for ACT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACT Stock Overview
Market Cap in USD | 5,235m |
Sector | Financial Services |
Industry | Insurance - Specialty |
GiC Sub-Industry | Property & Casualty Insurance |
IPO / Inception | 2021-09-16 |
ACT Stock Ratings
Growth 5y | 72.7% |
Fundamental | 72.3% |
Dividend | 32.9% |
Rel. Strength | -4.3 |
Analysts | 3.6/5 |
Fair Price Momentum | 36.97 USD |
Fair Price DCF | 104.41 USD |
ACT Dividends
Dividend Yield 12m | 2.18% |
Yield on Cost 5y | 4.42% |
Annual Growth 5y | -6.38% |
Payout Consistency | 89.9% |
ACT Growth Ratios
Growth Correlation 3m | 73.9% |
Growth Correlation 12m | 55.8% |
Growth Correlation 5y | 96.5% |
CAGR 5y | 22.92% |
CAGR/Max DD 5y | 1.13 |
Sharpe Ratio 12m | 0.97 |
Alpha | 8.82 |
Beta | 0.591 |
Volatility | 21.44% |
Current Volume | 222.3k |
Average Volume 20d | 193.3k |
As of April 01, 2025, the stock is trading at USD 34.75 with a total of 222,328 shares traded.
Over the past week, the price has changed by +0.81%, over one month by +1.08%, over three months by +7.92% and over the past year by +15.56%.
Yes, based on ValueRay Fundamental Analyses, Enact Holdings (NASDAQ:ACT) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 72.25 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACT as of April 2025 is 36.97. This means that ACT is currently overvalued and has a potential downside of 6.39%.
Enact Holdings has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold ACT.
- Strong Buy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ACT Enact Holdings will be worth about 40.3 in April 2026. The stock is currently trading at 34.75. This means that the stock has a potential upside of +16.06%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 38.6 | 11.1% |
Analysts Target Price | 38.6 | 11.1% |
ValueRay Target Price | 40.3 | 16.1% |